Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract s ...

Management is pivoting toward a global oncology enterprise, transitioning from a discovery-focused biotech to a commercial-stage organization with 8 ongoing or planned Phase III trials. The 'virtuous cycle' of innovation is driven by the tri-complex platform, which has enabled the rapid advancement of four clinical-stage RAS(ON) inhibitors targeting major oncogenic drivers. Pancreatic cancer remains the primary strategic focus, with daraxonrasib showing an unprecedented clinical profile that earned FD ...

Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights February 26, 2026 © 2026 NOVAVAX. All rights reserved This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate st ...

Q4 AND FULL YEAR 2025 EARNINGS CALL Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Se ...

Achieved 123% year-over-year revenue growth in 2025, driven by ZORYVE becoming the #1 branded nonsteroidal topical across psoriasis, seborrheic dermatitis, and atopic dermatitis. Attributed commercial success to the 'steroid-sparing' movement, where providers and patients are actively seeking safe, long-term alternatives to topical corticosteroids. Maintained a stable gross-to-net in the 50s throughout 2025, validating a pricing strategy designed to balance broad payer access with sustainable investor ...

Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "advance," "broaden," "build," "deliver," and "expand," and include statements argenx makes regarding its new era of innovation in immunology; its advancement of its Vision 2030, including (1) 5 new molec ...

Delivered $616 million in total global revenue for 2025, driven by $594 million in U.S. BRIUMVI net sales, representing 92% year-over-year growth. Performance was characterized by consistent increases in new patient starts and a broadening prescriber base across both academic and community settings. Management attributes sustained momentum to physician confidence in long-term data, specifically 6-year extension results showing 90% of patients remained disability-progression free. The company achieve ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals Earlier this month, the U.S. Food and Drug Administration initially refused to review rival Moderna's (MRNA.O), opens new tab mRNA-based flu vaccine, then reversed course a week later after the company amended its application. The biotech now expects 2026 adjusted revenue of $230 million to $270 million, up from its prio ...

Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10%. Within the Russell 1000 Growth Index, healthcare, communication services, and financials were the top-performing sectors, while utilities, real estate, and materials lagged. The U.S. economy show ...

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company found ...